Full Press Release Details
Biogen Idec Reports First Quarter 2010 Results TYSABRI® Revenues Increase 32% Year over Year.
BIIB
Biogen Idec Reports First Quarter 2010 Results TYSABRI® Revenues Increase 32% Year over Year
Key Takeaway: Biogen Idec Reports First Quarter 2010 Results TYSABRI® Revenues Increase 32% Year over Year
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis